Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf(National Center for Tumor Diseases), Caroline Robert(Institut Gustave Roussy), John B.A.G. Haanen(Leiden University Medical Center), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Jeffrey J. Legos(Novartis (United States)), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), E. Levchenko(Research Medical Center), Axel Hauschild(University Hospital Schleswig-Holstein), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Antoni Ribas(University of California, Los Angeles), Bijoyesh Mookerjee(Novartis (United States)), Paul Nathan(Mount Vernon Hospital), Bogusława Karaszewska, Helen Gogas(National and Kapodistrian University of Athens), Ying Zhang, D. Stroiakovski(Moscow City Oncology Hospital №62), Claus Garbe(University of Tübingen), Mathilde Kaper(Novartis (United States)), Mario Mandalà(University of Perugia)
Cited by 171
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k